Navigation Links
Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
Date:1/31/2013

OSLO, January 31, 2013 /PRNewswire/ --

18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013.

Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer patients."

Hanne Mette D Kristensen, CEO, says: "We are proud that Targovax now has its first drug in clinical Phase I/II, only two years after the company's inception. The study will run at the Radium Hospital at Oslo University Hospital, international pioneers in development of immunotherapy and cancer vaccines. TG01 has already shown promising results in patients. If these results are confirmed by systematic studies, TG01 may mean the first real change for pancreatic cancer patients."

Targovax is owned by The Radium Hospital Research Foundation, Birk Venture and RO Invest, inventors and management. The company has received grant from Innovation Norway for running the clinical Phase I/II trial in collaboration with OUS, The Radium Hospital.

Targovax

Targovax is a cancer biotech-company started in October 2010. The TG01 cancer vaccine is therapeutic; it is given as treatment to patients who already have cancer to prevent recurrence, and educates the body's immune system to recognize and kill cancer cells.

Approximately 80-90% of pancreatic cancers have RAS mutations. Cancers with RAS mutations have proved to be difficult to treat with current treatment, and there is a significant unmet medical need.

A follow-up review of clinical trials from the end of the 90'es indicates increased survival for patients treated with TG01. Some of these patients are still alive more than ten years later. This is promising within a disease with very poor prognosis.

TG01 has received Orphan Drug Status for pancreatic cancer in EU and USA. Targovax owns patents and the documentation from earlier development of TG01.

Contact:

Targovax
Hanne Mette D. Kristensen , CEO, cell phone: +47-97-19-74-49,
E-mail: hmkristensen@targovax.com, http://www.targovax.com

The Norwegian Radium Hospital, Clinical Cancer Research Unit, Svein Dueland : +47-915-02770


'/>"/>
SOURCE Targovax AS
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):